Tags: study + drug company.with.MS

Sort by: Date / Title / URL

1. Merck KGaA's Rebif, Teva's Copaxone similar-study | Health | Reuters
   The number of events (relapses) was insufficient to establish a statistically significant difference between the two products, despite a trend advantage for Rebif
   11-10-2007 to copaxone, drug company, drugs, interferon, rebif, study, treatment by admin
2. Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
   The BENEFIT study (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment.
   03-08-2007 to betaseron, drug company, drugs, interferon, ms, multiple sclerosis, newly diagnosed, study, treatment by admin
3. Reuters AlertNet - Rituxan shows promise in multiple sclerosis trial
   Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potentially more effective way of treating the progressive neurological disease.
   03-05-2007 to drug company, drugs, multiple sclerosis, research, rituxan, rrms, study by admin
4. Roskamp Institute Looking for Volunteers for Multiple Sclerosis Research Study
   The Roskamp Institute announced today its participation in a pharmaceutical sponsored research study for relapsing-remitting Multiple Sclerosis (MS) sufferers.
   08-12-2006 to clinical trial, drug company, drugs, fingolimod, multiple sclerosis, relapsing remitting, research, rrms, study by admin
5. Opexa begins dosing in trial for multiple sclerosis - Pharmaceutical Business Review
   The phase IIb clinical study will be designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T Cell vaccination with clinically isolated syndrome and relapsing-remitting multiple sclerosis patients.
   08-11-2006 to clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, rrms, study, tovaxin by admin
6. Teva Says Copaxone Slows Tissue Damage - MSN Money
   Generic drug maker Teva Pharmaceutical Industries Ltd. said Monday new data from a study of its multiple sclerosis drug reinforce previous information that the treatment reduces relapses of symptoms and may slow tissue damage associated with the disease.
   03-10-2006 to copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, relapsing remitting, research, rrms, study, treatment by admin
7. News - Glatiramer Acetate Shows Positive Impact on Average Relapse Rate and Disease Progression in Multiple Sclerosis For Up to 5 Years: Presented at ECTRIMS
   Treatment of relapsing-remitting multiple sclerosis (MS) with glatiramer-acetate (glatiramer, Copaxone) is safe and effective, and it has a positive impact on average relapse rate and disease progression scores.
   01-10-2006 to copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, pregnancy, relapsing remitting, research, rrms, study, treatment by admin
8. Very Active Multiple Sclerosis Patients Benefited from COPAXONE(R) Treatment Following Short-Term Induction with Mitoxantrone. Genetic Engineering News - Biotechnology from Bench to Business
   A new study showed that very active patients who received COPAXONE(R) (glatiramer acetate injection) therapy alone following short-term induction treatment with mitoxantrone experienced an 89 percent greater reduction (Pless than0.0001) compared to those
   30-09-2006 to copaxone, drug company, drugs, mitoxantrone, multiple sclerosis, relapsing remitting, research, rrms, study, treatment by admin
9. PharmaLive: Betaferon Demonstrates Robust Reduction in Risk of Developing Multiple Sclerosis Across All Subgroups of Benefit study
   Schering AG Germany, announced today results from the subgroup analysis of the BENEFIT* study which showed that Betaferon® (interferon beta-1b) 250mcg treatment reduced the risk of developing clinically definite MS (CDMS) consistent
   30-09-2006 to betaseron, drug company, drugs, interferon, multiple sclerosis, newly diagnosed, relapsing remitting, research, rrms, study, treatment by admin
10. New Study: AVONEX(R), The Most Prescribed Multiple Sclerosis Treatment Worldwide, Demonstrates Superior Adherence
    Biogen Idec (NASDAQ: BIIB) announced findings today from the Global Adherence Project (GAP) that demonstrated patients taking AVONEX(R) (interferon beta-1a), the most prescribed multiple sclerosis (MS) treatment worldwide, adhered to treatment more than p
    29-09-2006 to avonex, drug company, drugs, relapsing remitting, study, treatment by admin
11. Campath showing potential to treat multiple sclerosis - San Antonio Business Journal:
    Data analyzed after two years showed a 75 percent reduction in the risk of relapse for patients taking Campath compared to patients treated with Rebif, Genzyme says.
    14-09-2006 to campath, clinical trial, drug company, drugs, multiple sclerosis, rebif, research, study, treatment by admin
12. Genentech, Biogen say cancer drug helps against MS | Health | Reuters.co.uk
    Biotechnology companies Genentech Inc. and Biogen Idec Inc. on Monday said their cancer drug Rituxan showed hints of effectiveness against multiple sclerosis in a small mid-stage trial
    28-08-2006 to canada, chemotherapy, clinical trial, drug company, drugs, multiple sclerosis, research, rituxan, study, treatment, us by admin
13. Chromos Updates On Progress With Development Of CHR-1103 For Treatment Of MS
    A humanized monoclonal antibody, CHR-1103 is being developed for the acute treatment of relapsing forms of multiple sclerosis (MS).
    18-08-2006 to chr-1103, drug company, drugs, multiple sclerosis, study, treatment, us by admin
14. Clinical Trial: Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
    The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treatment of R-R MS.
    07-08-2006 to clinical trial, copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, relapsing remitting, research, rrms, study by admin
15. Teva Initiates Phase III Study To Confirm Increased Efficacy Of Higher Dose Of Glatiramer Acetate For Relapsing-Remitting Multiple Sclerosis
    Teva Pharmaceutical Industries Ltd. announced the initiation of a large Phase III study designed to confirm the positive results from the Phase II study which compared a new higher dose of 40 mg/day dose of glatiramer acetate (GA) to the currently approve
    07-08-2006 to clinical trial, copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, relapsing remitting, research, rrms, study, treatment by admin

First / Previous / Next / Last / Page 1 of 2